These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25137254)

  • 1. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics.
    Cho HP; Garcia-Barrantes PM; Brogan JT; Hopkins CR; Niswender CM; Rodriguez AL; Venable DF; Morrison RD; Bubser M; Daniels JS; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Biol; 2014 Oct; 9(10):2334-46. PubMed ID: 25137254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCA44- and SCAR13-associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms.
    Wang Y; Muraleetharan A; Langiu M; Gregory KJ; Hellyer SD
    Br J Pharmacol; 2024 Nov; 181(22):4514-4530. PubMed ID: 39030902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.
    Garcia-Barrantes PM; Cho HP; Niswender CM; Byers FW; Locuson CW; Blobaum AL; Xiang Z; Rook JM; Conn PJ; Lindsley CW
    J Med Chem; 2015 Oct; 58(20):7959-71. PubMed ID: 26426481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the mGlu
    Yohn SE; Foster DJ; Covey DP; Moehle MS; Galbraith J; Garcia-Barrantes PM; Cho HP; Bubser M; Blobaum AL; Joffe ME; Cheer JF; Jones CK; Lindsley CW; Conn PJ
    Mol Psychiatry; 2020 Nov; 25(11):2786-2799. PubMed ID: 30116027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.
    Gregory KJ; Nguyen ED; Reiff SD; Squire EF; Stauffer SR; Lindsley CW; Meiler J; Conn PJ
    Mol Pharmacol; 2013 May; 83(5):991-1006. PubMed ID: 23444015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology.
    Muraleetharan A; Wang Y; Rowe MC; Gould A; Gregory KJ; Hellyer SD
    Mol Pharmacol; 2023 Jun; 103(6):325-338. PubMed ID: 36921922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGlu
    Maksymetz J; Byun NE; Luessen DJ; Li B; Barry RL; Gore JC; Niswender CM; Lindsley CW; Joffe ME; Conn PJ
    Cell Rep; 2021 Nov; 37(5):109950. PubMed ID: 34731619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.
    Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F
    Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead optimization of the VU0486321 series of mGlu
    Davis DC; Bungard JD; Chang S; Rodriguez AL; Blobaum AL; Boutaud O; Melancon BJ; Niswender CM; Jeffrey Conn P; Lindsley CW
    Bioorg Med Chem Lett; 2021 Jan; 32():127724. PubMed ID: 33253881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
    Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core.
    Garcia-Barrantes PM; Cho HP; Blobaum AL; Niswender CM; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5107-10. PubMed ID: 26476971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.
    Garcia-Barrantes PM; Cho HP; Metts AM; Blobaum AL; Niswender CM; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2016 Feb; 26(3):751-756. PubMed ID: 26778256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
    Gregory KJ; Noetzel MJ; Rook JM; Vinson PN; Stauffer SR; Rodriguez AL; Emmitte KA; Zhou Y; Chun AC; Felts AS; Chauder BA; Lindsley CW; Niswender CM; Conn PJ
    Mol Pharmacol; 2012 Nov; 82(5):860-75. PubMed ID: 22863693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.
    Werthmann RC; Tzouros M; Lamerz J; Augustin A; Fritzius T; Trovò L; Stawarski M; Raveh A; Diener C; Fischer C; Gassmann M; Lindemann L; Bettler B
    Neuropharmacology; 2021 Jun; 190():108426. PubMed ID: 33279506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1
    Bossi S; Musante I; Bonfiglio T; Bonifacino T; Emionite L; Cerminara M; Cervetto C; Marcoli M; Bonanno G; Ravazzolo R; Pittaluga A; Puliti A
    Neurobiol Dis; 2018 Jan; 109(Pt A):44-53. PubMed ID: 28982591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mGlu
    Luessen DJ; Gallinger IM; Ferranti AS; Foster DJ; Melancon BJ; Lindsley CW; Niswender CM; Conn PJ
    Neuropsychopharmacology; 2022 Sep; 47(10):1826-1835. PubMed ID: 35643819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deleterious GRM1 mutations in schizophrenia.
    Ayoub MA; Angelicheva D; Vile D; Chandler D; Morar B; Cavanaugh JA; Visscher PM; Jablensky A; Pfleger KD; Kalaydjieva L
    PLoS One; 2012; 7(3):e32849. PubMed ID: 22448230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.